Resalis Therapeutics is led by an experienced team with significant pharmaceutical industry, scientific and RNA medicine expertise. The company is also supported by a visionary Board as well as trusted advisors.
Leadership
Alessandro Toniolo
Chief Executive Officer
Alessandro Toniolo
Chief Executive Officer
Alessandro joined Resalis as CEO in October 2022 after 20 years in positions with increasing responsibility in the pharma industry. He worked in commercial roles at Italian, European and global companies including Merck, Pfizer, Shire and Novartis. Prior to joining Resalis, Alessandro was Novartis’ Head of Immunology as well as Head of Respiratory and Allergy franchises in Italy. He is also a Business Angel supporting multiple oncology startup companies on behalf of Italian Angels for Growth. Alessandro holds an MSc in Chemistry from the University of Pisa and a PhD in Chemistry from the University of Milan.
Riccardo Panella
Chief Scientific Officer and Co-Founder
Riccardo Panella
Chief Scientific Officer and Co-Founder
Riccardo is co-founder and CSO of Resalis. He serves as Associate Professor at the Center for RNA Medicine, in the Department of Clinical Medicine of Aalborg University. His research activities are focus on exploring the contribution of non-coding RNA ,specifically microRNA, to human metabolism and cancer progression. His aim is to develop new RNA based therapies for unmet medical needs. Before joining Aalborg University, Riccardo carried on his research activities at Beth Israel Deaconess Medical Center, part of the Harvard Medical School, where he developed and characterized several genetic engineered mouse models and executed a vast plethora of pre-clinical in-vivo experiments designed to optimize new therapeutic paradigm for metabolic disfunctions. Riccardo is part of an international research group led by Prof Kauppinen to developing new therapeutic approaches in the NASH/NAFLD space.
Sakari Kauppinen
Chief Technology Officer & Co-Founder
Sakari Kauppinen
Chief Technology Officer & Co-Founder
Sakari is co-founder and CTO of Resalis. He serves as Professor at the Department of Clinical Medicine, Aalborg University and Director of the Center for RNA Medicine. His research program focuses on exploring the roles of noncoding RNAs in human health and disease and discovering RNA-targeted therapeutics for unmet medical needs. Before joining Aalborg University, Sakari was Senior Director of microRNA Research and Drug Discovery at Santaris Pharma (acquired by Roche in 2014), where he supervised the discovery of miravirsen – the world’s first microRNA-targeted drug. He was also a member of the clinical development team that successfully advanced miravirsen to clinical phase 2 trials with on-target efficacy against HCV infection and a good safety profile. Sakari is co-founder of NEUmiRNA Therapeutics and received $9.2M in 2019 from the Novo Nordisk Foundation’s Challenge Program for a Research Consortium to advance development of new therapies for the treatment of NASH.
Barbara Domizzi
Project Coordinator and Budget Planner
Barbara Domizzi
Project Coordinator and Budget Planner
Barbara joined Resalis in May 23 as Project Coordinator and Budget Planner. She worked in marketing and admin/finance roles at several global and European pharma companies such as Basf, Abbott, Novartis. Before joining Resalis she was Novartis’ Budget Planner in Respiratory and Immunology Franchise.
Board of Directors
Pietro Puglisi
Chairman
Pietro Puglisi
Chairman
Pietro is a founding partner at Claris Ventures, an investment firm based in Turin, Italy, with a focus on early-stage biotech ventures. He has over a decade of experience in life sciences investments and innovation. Prior to launching Claris Ventures, he was involved in the financing rounds of several biopharma startup companies based in Italy where he played active roles, including as an independent director at Kither Biotech and Restorative Neurotechnologies. He started his career at LifeSciences Consultants in 2010 and later joined the healthcare practice of Innogest Capital. Pietro holds an MSc in Biomedical Engineering from Politecnico di Torino and an MBA from Collége des Ingenièurs, France/Italy.
Michael Hodges
Non-Executive Director
Michael Hodges
Non-Executive Director
Michael is a Partner at Claris Ventures and a pharmaceutical industry veteran with experience in management and scientific research at both big pharma and innovative biotech companies. He currently supports a number of biotechnology companies in the role of drug development consultant, and/or board director and is on the scientific advisory boards of several therapeutics-focused life science companies. He is also a scientific advisor for Adjuvant Capital and Novo Repair fund. Michael was previously the CMO of Amplyx Pharmaceuticals (acquired by Pfizer) and the CMO and head of development for Santaris Pharma (acquired by Roche). Michael started his career at Pfizer Global Research and Development where he worked on multiple infectious diseases and oncology development programs and under his leadership two antifungal drugs where approved, VFEND® (voriconazole) and ERAXIS™ (anidulafungin). He earned his MD degree and BSc in Pharmacology, from the University of London, UK.
Antonio Leone
Non-Executive Director
Antonio Leone
Non-Executive Director
Antonio is the President in IAG – Italian Angels for Growth since 2014. Antonio was BELLCO Chairman of the Charme fund managed by Montezemolo & Partners SGR and currently holds, among others, the position of board member of Cellply Srl. He was previously the President and CEO of Kontron Instruments, a member of the Roche Group. Prior to this, he was CEO of Olympus Medical System Europe in Hamburg that had a turnover of 700 million euros and 2300 employees. Antonio is an electronics engineer with over 40 years of experience in the electromedical equipment industry.